Office of Dietary Supplements

DUBLIN--( BUSINESS WIRE )--The "The Global EPA+DHA Omega-3 Finished Products Report - Data for 2020 and 2021 with forecasts through 2023" report has been added to ResearchAndMarkets.com's offering. The EPA and DHA omega-3 finished product market size reached US$47 billion in 2021. Growth remains strongest in developing markets in Asia, Africa, and the Middle East, leading the global EPA and DHA consumer product market to a projected annual growth rate of 3.2% for 2022-2023. How can I learn more? The Finished Product Report provides a description of the size and value of the global finished product market for EPA and DHA oils. For the purposes of this report, an omega-3 finished product is a product containing EPA and/or DHA omega-3s, which are often used as an ingredient in dietary supplements, fortified foods and beverages, pharmaceuticals, clinical nutrition/medical food, infant formula and pet food/supplements. Finished product sales estimates and projections are detailed by finished product category. The report also includes forecasts through 2023 and an analysis of the geographic trends and factors influencing market growth. Charts and figures include: Figures by Region United States Canada Mexico South America Europe Australia New Zealand China Japan Rest of APAC Rest of Asia Rest of World Figures by Finished Product Category Dietary Supplement Food & Beverage Pet Food Infant Formula Pharmaceutical Clinical Nutrition/Medical Food Key Topics Covered: Scope and Methodology Scope Report Methodology Market Overview Regional Trends Product Category Trends Major Market Dynamics Category Focus Infant Formula Pet Food Food and Beverage Dietary Supplements Pharmaceuticals Clinical Nutrition and Medical Food Sales + Growth by Product Category Sales by Region Acknowledgements About the Report For more information about this report visit https://www.researchandmarkets.com/r/s26ggd

SILVER SPRING, Md., Nov. 17, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration issued warning letters to seven companies for illegally selling dietary supplements that claim to cure, treat, mitigate or prevent cardiovascular disease or related conditions, such as atherosclerosis, stroke or heart failure, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA is urging consumers not to use these or similar products because they have not been evaluated by the FDA to be safe or effective for their intended use and may be harmful. The warning letters were issued to: Essential Elements (Scale Media Inc.); Calroy Health Sciences LLC; Iwi; BergaMet North America LLC; Healthy Trends Worldwide LLC (Golden After 50); Chambers' Apothecary; and Anabolic Laboratories, LLC. "Given that cardiovascular disease is the leading cause of death in the U.S., it's important that the FDA protect the public from products and companies that make unlawful claims to treat it. Dietary supplements that claim to cure, treat, mitigate or prevent cardiovascular disease and related conditions could potentially harm consumers who use these products instead of seeking safe and effective FDA-approved treatments from qualified health care providers," said Cara Welch, Ph.D., director of the Office of Dietary Supplement Programs in the FDA's Center for Food Safety and Applied Nutrition. "We encourage consumers to remain vigilant when shopping online or in stores to avoid purchasing products that could put their health at risk." Under the FD&C Act, products intended to diagnose, cure, treat, mitigate or prevent disease are drugs and are subject to the requirements that apply to drugs, even if they are labeled as dietary supplements. Unlike drugs approved by the FDA, the agency has not evaluated whether the unapproved products subject to the warning letters announced today are effective for their intended use, what the proper dosage might be, how they could interact with FDA-approved drugs or other substances, or whether they have dangerous side effects or other safety concerns. The FDA advises consumers to talk to their doctor, pharmacist or other health care provider before deciding to purchase or use any dietary supplement or drug. Some supplements might interact with medicines or other supplements. Health care providers will work with patients to determine which treatment is the best option for their condition. If a consumer thinks that a product might have caused a reaction or an illness, they should immediately stop using the product and contact their health care provider. The FDA encourages health care providers and consumers to report any adverse reactions associated with FDA-regulated products to the agency using MedWatch or the Safety Reporting Portal. The FDA has requested responses from the companies within 15 working days stating how they will address the issues described in the warning letters or provide their reasoning and supporting information as to why they think the products are not in violation of the law. Failure to correct violations promptly may result in legal action, including product seizure and/or injunction. Related Information Constituent Update Dietary Supplements Media Contact: Courtney Rhodes, 202-281-5237 Consumer Inquiries: 888-INFO-FDA The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products. SOURCE U.S. Food and Drug Administration